Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
LA JOLLA PHARMACEUTICAL CO (LJPC)
Sector: Healthcare; Industry: Biotechnology

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2020-09-08 RAMSAY DAVID A Director Buy 1,000 $3.83 $3,830 No
2020-09-09 TANG KEVIN C Chief Financial Officer Buy 278,369 $3.94 $1,096,829 No
2020-08-24 RAMSAY DAVID A Director Buy 47,000 $3.99 $187,456 No
2020-08-14 TANG KEVIN C Chief Financial Officer Buy 431,647 $3.72 $1,605,100 No
2020-06-04 TANG KEVIN C Chief Financial Officer Buy 615,129 $4.91 $3,017,479 No
2020-02-03 TANG KEVIN C 10%-Owner, Director Buy 169,770 $6.76 $1,146,968 No
2020-01-14 Wellinghoff Darryl Chief Commercial Officer Buy 3,000 $8.23 $24,676 No
2020-01-13 TANG KEVIN C 10%-Owner, Director Buy 2,971,682 $5.87 $17,434,468 No
2019-01-30 Chawla Lakhmir S Chief Medical Officer Buy 3,000 $5.56 $16,694 No
2019-01-09 TANG KEVIN C 10%-Owner, Director Buy 1,300,000 $5.37 $6,985,285 No
2019-01-07 TIDMARSH GEORGE F President, CEO & Secretary Buy 2,000 $5.85 $11,700 No
2019-01-09 CARVER JENNIFER Chief Operating Officer Buy 5,000 $6.17 $30,825 No
2019-01-09 Rolke James Chief Scientific Officer Buy 1,600 $6.09 $9,746 No
2019-01-08 PERCEPTIVE ADVISORS LLC 10%-Owner Sell 2,060,235 $5.69 $11,715,985 No
2018-08-16 Rolke James Chief Scientific Officer Buy 1,000 $22.00 $21,997 No
2018-08-16 CARVER JENNIFER Chief Operating Officer Buy 1,000 $20.90 $20,895 No
2018-03-15 PERCEPTIVE ADVISORS LLC 10%-Owner Buy 700,000 $29.50 $20,650,000 No
2018-03-15 TANG KEVIN C 10%-Owner, Director Buy 508,474 $29.50 $14,999,983 No
2018-03-02 TANG KEVIN C 10%-Owner, Director Buy 40,000 $30.06 $1,202,527 No
2018-02-23 CARVER JENNIFER Chief Operating Officer Buy 1,000 $32.48 $32,475 No
2018-02-27 TANG KEVIN C 10%-Owner, Director Buy 150,000 $31.82 $4,772,334 No
2018-02-15 PERCEPTIVE ADVISORS LLC 10%-Owner Buy 50,000 $32.42 $1,621,000 No
2018-02-14 PERCEPTIVE ADVISORS LLC 10%-Owner Buy 175,000 $32.72 $5,725,250 No
2017-12-29 Douglass Laura L. Director Sell 10,000 $32.32 $323,208 Yes
2017-12-27 CARVER JENNIFER Chief Operating Officer Buy 1,000 $33.22 $33,215 No
2017-03-23 TANG KEVIN C 10%-Owner, Director Buy 149,254 $33.50 $5,000,009 No
2017-03-03 TIDMARSH GEORGE F President, CEO & Secretary Buy 3,000 $34.17 $102,505 No
2017-03-02 CARVER JENNIFER Chief Operating Officer Buy 1,000 $34.46 $34,460 No
2017-03-03 Chawla Lakhmir S Chief Medical Officer Buy 1,600 $34.80 $55,678 No
2017-03-03 MULROY DENNIS Chief Financial Officer Buy 500 $33.95 $16,975 No

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.